Loading clinical trials...
Loading clinical trials...
Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ): a Prospective, Single-center Clinical Study
Conditions
Interventions
Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)
Locations
1
China
First Hospital of Jilin University
Changchun, Jilin, China
Start Date
May 1, 2021
Primary Completion Date
May 1, 2024
Completion Date
December 1, 2024
Last Updated
July 20, 2022
Lead Sponsor
The First Hospital of Jilin University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions